Longevity medicine is arriving in pet care
Longevity medicine is moving from theory to veterinary practice, and that’s the core message in Dr. Kevin Toman’s recent appearance on Vet Life Reimagined. Toman, a longtime companion animal veterinarian who now focuses on senior pet care, argues that veterinarians are beginning to adapt lessons from the much larger human longevity field for dogs and cats, with the immediate focus on extending healthspan, not just lifespan. That shift is happening alongside real regulatory and research progress: biotech company Loyal says its dog longevity programs are advancing through FDA’s expanded conditional approval pathway, with LOY-001 for large dogs receiving a reasonable expectation of effectiveness milestone in 2023, and LOY-002 for senior dogs 10 years and older, weighing at least 14 pounds, reaching the same milestone in February 2025. Loyal also says LOY-002’s Target Animal Safety package was accepted by FDA in December 2025, leaving manufacturing as the remaining major step before a possible conditional approval decision. (music.amazon.co.uk)
Why it matters: For veterinary professionals, longevity medicine is becoming less of a fringe conversation and more of a practical framework for senior care. The field now spans prescription drug development, clinical trials, frailty and quality-of-life measurement, nutrition, and preventive monitoring. FDA’s expanded conditional approval pathway is especially relevant because it allows marketing of a drug after safety, manufacturing quality, and a “reasonable expectation of effectiveness” are shown, while fuller effectiveness data are still being gathered. At the same time, academic work remains active: the Dog Aging Project’s TRIAD trial is testing rapamycin in healthy middle-aged dogs, and Texas A&M reported in January 2025 that the project received a $7 million NIH grant to expand that study. Professional guidance is also catching up; AAHA’s senior care guidelines emphasize individualized care, frequent reassessment, and quality of life as central goals in older pets. (fda.gov)
What to watch: Watch for whether FDA grants conditional approval to the first canine longevity drug in 2026, and for readouts from larger controlled studies that could show how longevity medicine fits into everyday primary care. (loyal.com)